Results 31 to 40 of about 29,593 (220)

Mitteilungen aus der Arbeitsgemeinschaft Evidenzbasierte Medizin der AGMB

open access: yesGMS Medizin – Bibliothek – Information, 2021
The activities of the recently founded Evidence Based Medicine Working Group within the German Medical Library Association (AGMB) continued in the first half of 2021 with a whole series of virtual training events and exchange of training materials.
Buroh, Sabine   +2 more
doaj   +1 more source

Medizinbibliotheken – Konstant im Wandel

open access: yesGMS Medizin – Bibliothek – Information, 2013
[english] The focus of the current issue 3/2013 of GMS Medizin – Bibliothek – Information is the annual conference 2013 of the German Medical Libraries Association in Berlin.
Bauer, Bruno
doaj   +1 more source

AGMB-Wettbewerb „Leuchtturmprojekte an Medizinbibliotheken 2023“: Würdigung des Projektes „CAS Systematic Review Information Specialist“

open access: yesGMS Medizin – Bibliothek – Information, 2023
The project of the winners of the competition “Pioneer Projects in Medical Libraries 2023” will be presented and the jury’s reasoning for awarding the prize will be outlined.
Jirausch, Claudia
doaj   +1 more source

AGMB-Wettbewerb „Leuchtturmprojekte an Medizinbibliotheken 2022“: Würdigung des Projektes LIGHTS

open access: yesGMS Medizin – Bibliothek – Information, 2022
The project of the winners of the competition “Pioneer projects in medical libraries 2022” is presented and the jury’s reasoning for awarding the prize is outlined.
Jirausch, Claudia
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

open access: yesMolecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak   +10 more
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

open access: yesMolecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena   +15 more
wiley   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

open access: yesMolecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel   +12 more
wiley   +1 more source

Aus der AGMB

open access: yesGMS Medizin – Bibliothek – Information
The 2024 conference in Mainz is reported on and thoughts for the future development of the conference are discussed.
Jirausch, Claudia
doaj   +3 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy